Market Place
Sourcing Support
Ultragenyx Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
24 Apr 2026 //
GLOBENEWSWIRE
Rosen Law Firm Urges Ultragenyx Pharma Stockholders
03 Apr 2026 //
PHARMIWEB
Ultragenyx Resubmits UX111 AAV Gene Therapy BLA For MPS IIIA
02 Apr 2026 //
GLOBENEWSWIRE
FDA Clears Ultragenyx`s UX016 IND for GNE Myopathy
30 Mar 2026 //
GLOBENEWSWIRE
Ultragenyx Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
20 Mar 2026 //
GLOBENEWSWIRE
Ultragenyx Gene Therapy Cuts Ammonia in Phase 3 Trial
13 Mar 2026 //
FIERCE BIOTECH
Ultragenyx`s DTX401 AAV Gene Therapy For Gsdia Accepted By FDA
23 Feb 2026 //
GLOBENEWSWIRE
Ultragenyx Lays Off 10% Of Workers As FDA Stalls Approval Plan
13 Feb 2026 //
FIERCE BIOTECH
RARE Investors Lead Ultragenyx Pharma Securities Fraud Lawsuit
06 Feb 2026 //
PHARMIWEB
Ultragenyx Report UX111 Gene Therapy Sustains in CSF-HS Reduction
03 Feb 2026 //
GLOBENEWSWIRE
Ultragenyx Resubmits UX111 AAV Therapy For Sanfilippo Syndrome
30 Jan 2026 //
GLOBENEWSWIRE
Ultragenyx Submits BLA to FDA for DTX401 Therapy in GSDIa
30 Dec 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Setrusumab (UX143) Phase 3 Results
29 Dec 2025 //
GLOBENEWSWIRE
Ultragenyx Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
21 Nov 2025 //
GLOBENEWSWIRE
Ultragenyx Sells Future Crysvita Royalties For $400 Million
04 Nov 2025 //
GLOBENEWSWIRE
Ultragenyx`s 1st Patient Dosed in Aurora Study Evaluating GTX-102
30 Oct 2025 //
GLOBENEWSWIRE
Ultragenyx Fill Ph3 Aspire Study for GTX-102 in Angelman Syndrome
31 Jul 2025 //
GLOBENEWSWIRE
Health Canada Expands Evkeeza Approves for Kids With HoFH
14 Jul 2025 //
GLOBENEWSWIRE
Ultragenyx, Mereo Plummet After Rare Diseases Trial Result
11 Jul 2025 //
GLOBENEWSWIRE
Ultragenyx Earns Breakthrough Status for GTX-102 in Angelman
27 Jun 2025 //
GLOBENEWSWIRE
Ultragenyx Highlights Rare Disease Innovation in 2024 Report
14 May 2025 //
GLOBENEWSWIRE
FDA Grant Priority Review To Ultragenyx`s BLA For UX111 In MPS IIIA
18 Feb 2025 //
GLOBENEWSWIRE
Ultragenyx Shows UX111 Therapy Improves Sanfilippo Syndrome Type A
05 Feb 2025 //
GLOBENEWSWIRE
Ultragenyx Receives Breakthrough Designation For Setrusumab
07 Oct 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Rule
18 Sep 2024 //
GLOBENEWSWIRE
Ultragenyx to Present at Guggenheim`s Genomic Medicines and Rare Disease Days
28 Mar 2023 //
GLOBENEWSWIRE
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
28 Feb 2023 //
GLOBENEWSWIRE
C-Path and Ultragenyx Announce Agreement to Support Rare Disease Treatment
01 Dec 2022 //
PRESS RELEASE
Ultragenyx pauses trial after patients lose ability to walk
28 Oct 2020 //
FIERCE BIOTECH
Ultragenyx wins early approval for rare disease drug
01 Jul 2020 //
BIOPHARMADIVE
Rare disease drugmaker Ultragenyx builds case for its gene therapy franchise
15 May 2020 //
ENDPTS
Teva successfully used a rare pediatric PRV to speed the approval for Ajovy
21 Nov 2018 //
RAPS
Ultragenyx stumbles with UX007 PhIII, shares plunge
27 Oct 2018 //
ENDPTS
Ultragenyx dumps rare nervous system disorder program after phase 3 flop
26 Oct 2018 //
FIERCE BIOTECH
FDA approves Ultragenyx`s drug for rare form of rickets
18 Apr 2018 //
REUTERS
Ultragenyx`s rhGUS Gets FDA Nod for Rare Genetic Disease
17 Nov 2017 //
NASDAQ
PhIII bust forces Ultragenyx to scrap drug for rare muscle disease
22 Aug 2017 //
ENDPTS
